Monday, January 16, 2012

User-fee agreement heads to Congress for approval

Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/drAfCduTtWCcdQmLCidawyCicNdOKI

January 16, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • User-fee agreement heads to Congress
    A final agreement between the FDA and the pharmaceutical industry on user fees for prescription, generic and biosimilar drugs was submitted for approval by Congress. "At a time of greater budgetary constraint, user fees provide a critical way for leveraging appropriated dollars, ensuring that the FDA has the resources needed to conduct reviews in a timely fashion," FDA Commissioner Margaret Hamburg said. The Hill/Healthwatch blog (1/13), Reuters (1/14), The Washington Post/The Associated Press (1/13) LinkedInFacebookTwitterEmail this Story
See how Cardmembers use American Express OPEN Cards to help run their business:
“I'm a doctor, and my time's pretty valuable, so it's great to be able to rely on the Card, especially where book-keeping is concerned.” - Dr. Lynn McMahan, Southern Eye Center

With the Business Platinum Card, easily manage and track business expenses with your online card account.
LEARN MORE & APPLY
  Health Care & Policy 
 
  • Mass. biotech startup seeks to create "super drugs"
    Blend Therapeutics, established only last year, aims to develop drugs that can treat several illnesses, including cancer and inflammatory and infectious diseases. The company plans to combine multiple medications into single nanoparticles. Boston Herald (1/15) LinkedInFacebookTwitterEmail this Story
  • 282 child-specific drugs are in the pipeline, group says
    The biopharmaceutical industry has 282 drugs undergoing clinical development or FDA evaluation for conditions affecting the pediatric population, the Pharmaceutical Research and Manufacturers of America reported. The lineup includes therapeutic candidates for cancer, infectious diseases, genetic diseases and neurological illnesses. Researchers are also evaluating many existing drugs for use in children. PharmaTimes (U.K.) (1/13) LinkedInFacebookTwitterEmail this Story
  • Company to sell stem cell treatment
    Geron has hired Stifel Nicolaus & Co. to help it sell its embryonic stem cell treatment for spinal cord injuries. Geron in November announced it would end its stem cell program to focus on two cancer treatments. Bloomberg Businessweek (1/12) LinkedInFacebookTwitterEmail this Story
Principles of Checkweighing - Building an Effective Program
This essential guide is an invaluable resource of checkweighing information and a definitive reference providing an insight into all aspects of checkweighing from basic principles to implementation of a comprehensive program. Request your free copy now!
  Company & Financial News 
 
VoIP phone systems deliver impressive benefits for businesses large and small. From advanced features like unified communications to significant cost savings, there's a compelling case to switch to VoIP. Read through these free guides for the very latest information on the phone system market.
  Featured Content 
 
Most Popular Headlines from Last Week
Results based on number of times each story was clicked by readers.

  Food & Agriculture 
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • Study: Ethanol's octane potential can help U.S. meet fuel-economy goals
    Ethanol's high octane value could help the U.S. achieve its increasingly stringent fuel economy standards by powering high-efficiency internal combustion engines, according to a study conducted by AVL and partially funded by ICM. E30 gives a higher octane performance than iso-octane, the reference for 100-octane fuel, the study found. "These real-world results show that ethanol blends have the potential to offer much more octane value than previously estimated by methods prescribed by the [American Society for Testing and Materials]," said Steve Vander Griend, head of ICM's research and development of ethanol engines. DomesticFuel.com (1/13) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
We are always complaining that our days are few, and acting as though there would be no end of them."
--Seneca,
Roman philosopher, statesman and playwright


LinkedInFacebookTwitterEmail this Story

 
 
This SmartBrief was created for jmabs1@gmail.com
 
Subscriber Tools
     
Update account information | Change e-mail address | Unsubscribe | Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information

No comments: